Status:
COMPLETED
Rituxmab Versus IL-6 in Treating ILD
Lead Sponsor:
Assiut University
Conditions:
Interstitial Lung Disease
Scleroderma
Eligibility:
All Genders
20-70 years
Phase:
PHASE2
PHASE3
Brief Summary
All SSc patients should know if they have been diagnosed with interstitial lung disease, or pulmonary hypertension and keep results from his/her last pulmonary function test, chest imaging, echocardio...
Detailed Description
All SSc patients should know if they have been diagnosed with interstitial lung disease, or pulmonary hypertension and keep results from his/her last pulmonary function test, chest imaging, echocardio...
Eligibility Criteria
Inclusion
- active ILD scleroderma
Exclusion
- abnormal liver enzymes renal impairment neutropenia \<1000 cells/mm3 thrombocytopenia \< 50,000 cells/mm3
Key Trial Info
Start Date :
December 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05963048
Start Date
December 1 2021
End Date
June 1 2023
Last Update
November 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Manal Hassanien
Asyut, Yes, Egypt, 7111